NDA 218944 · Syndax
Revuforj
Revumenib Citrate · Oral
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Nov 15, 2024: To treat relapsed or refractory acute leukemia
Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Nov 15, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
27
3 Phase 3, 12 recruiting
FAERS reports
1,031
628 serious, 137 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DIFFERENTIATION SYNDROME, QTc PROLONGATION and TORSADES DE POINTES Differentiation syndrome, which can be fatal, has occurred with REVUFORJ. Signs and symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and renal dysfunction. If differentiation syndrome is suspected, immediately initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution. [see Dosage and Administration (2.3 ) , Warnings and Precautions (5.1) , and Adverse Reactions (6.1) ] . QTc prolongation and Torsades de Pointes have occurred in patients receiving REVUFORJ. Correct hypokalemia and hypomagnesemia prior to and during treatment. Do not initiate REVUFORJ in patients with QTcF > 450 msec. If QTc interval prolongation occurs, interrupt, reduce, or permanently discontinue REVUFORJ. [see...
What it is approved for
From the label in effect Feb 4, 2026.
REVUFORJ is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older. ( 1 ) the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options. ( 1 ) Relapsed or Refractory Acute Leukemia REVUFORJ is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older. REVUFORJ is indicated for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 ( NPM1 ) mutation [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) , and Clinical Studies (14.1) ] in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
Mechanism: Revumenib is a menin inhibitor that blocks the interaction of both wild-type lysine methyltransferase 2A (KMT2A) and KMT2A fusion proteins with menin. The binding of wild-type KMT2A or KMT2A fusion proteins with menin is involved in NPM1 mutated acute myeloid leukemias and KMT2A - rearranged acute leukemias, respectively, through activation of a leukemogenic transcriptional pathway. Susceptible NPM1 mutations are defined as those that result in loss of the nucleolar localization signal and the insertion of a new nuclear export signal leading to the accumulation of mutant NPM1 in the cytoplasm...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 24, 2025 Supplement 3 · Efficacy · priority review OrphanLabelMedication GuideLetter
- Nov 15, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
3 products under this application
- REVUFORJ · REVUMENIB CITRATE EQ 110MG BASE · TABLET, ORAL · Prescription
- REVUFORJ · REVUMENIB CITRATE EQ 160MG BASE · TABLET, ORAL · Prescription
- REVUFORJ · REVUMENIB CITRATE EQ 25MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Revumenib" as an intervention, any sponsor and status, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
- Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationPivotal-lookingRecruiting
Syndax PharmaceuticalsIndustry
NCT07211958 · 468 participants (planned) · Start Nov 25, 2025 · Primary completion Jun 2029
Drug: Revumenib; Placebo and 1 more · For: Acute Myeloid Leukemias
Sites: Goodyear, Arizona; Duarte, California; Farmington, Connecticut · 173 sites in all
- Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AMLPivotal-lookingRecruiting
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT06652438 · 448 participants (planned) · Start May 5, 2025 · Primary completion Dec 13, 2029
Drug: Revumenib; Placebo · For: Acute Myeloid Leukemia, Adult
Sites: Los Angeles, California; San Francisco, California; Atlanta, Georgia · 199 sites in all
Syndax PharmaceuticalsIndustry
NCT04065399 · 447 participants (planned) · Start Nov 5, 2019 · Primary completion Dec 15, 2027
Drug: revumenib; cobicistat · For: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Mixed Lineage Acute Leukemia and 2 more
Sites: Duarte, California; Los Angeles, California; Palo Alto, California · 57 sites in all
- Menin-Inhibitor Targeted Maintenance in AMLPivotal-lookingNot yet recruiting
Center for International Blood and Marrow Transplant ResearchResearch network
NCT07563010 · 146 participants (planned) · Start Dec 2026 · Primary completion Jun 2031
Drug: Revumenib; Placebo · For: Relapsed Adult AML; Stem Cell Transplant Complications; Acute Myeloid Leukemia and 1 more
- A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasActive, not recruiting
Syndax PharmaceuticalsIndustry
NCT06226571 · 96 participants · Start May 21, 2024 · Primary completion Feb 2027
Drug: Revumenib; Chemotherapy Regimen and 1 more · For: Acute Myeloid Leukemias
Sites: Goodyear, Arizona; Burbank, California; Duarte, California · 48 sites in all
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruiting
SWOG Cancer Research NetworkResearch network
NCT07636564 · 90 participants (planned) · Start Oct 14, 2026 · Primary completion Apr 16, 2031
Drug: Blinatumomab; Calaspargase Pegol and 11 more · For: Acute Leukemia of Ambiguous Lineage; B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative and 1 more
UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
NCT07605949 · 88 participants (planned) · Start Dec 2026 · Primary completion Jul 2028
Drug: Azacitidine; Venetoclax and 1 more · For: Leukemia Acute Myeloid
Sites: Chapel Hill, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use310
- nausea172
- platelet count decreased160
- product dose omission issue121
- fatigue110
- death104
- vomiting77
- white blood cell count decreased73
- pyrexia63
- haemoglobin decreased51
- diarrhoea50
- electrocardiogram qt prolonged49
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 10 |
| 2025 | 545 |
| 2026 | 476 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Revuforj (Revumenib Citrate)
2024 spending
$1.1M
Beneficiaries
17
29 claims
Per beneficiary
$64,230
$649.95 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,091,910 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Issa GC, Aldoss I, Thirman MJ, et al. · J Clin Oncol 2025 · Clinical Trial, Phase I, Clinical Trial, Phase II
- The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC, Aldoss I, DiPersio J, et al. · Nature 2023 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
Arellano ML, Thirman MJ, DiPersio JF, et al. · Blood 2025 · Clinical Trial, Phase II, Multicenter Study
- MEN1 mutations mediate clinical resistance to menin inhibition.
Perner F, Stein EM, Wenge DV, et al. · Nature 2023 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.
Zeidner JF, Lin TL, Welkie RL, et al. · J Clin Oncol 2025 · Clinical Trial, Phase I, Multicenter Study
- All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
Issa GC, Cuglievan B, El Hajjar G, et al. · J Clin Oncol 2026 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Syndax
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.